All Sections

Site Selection

Facility Planning

Workforce Development

Business+Place

AD Editorial Board

Alan Reeves

Senior Managing Director, Global Strategy, Newmark
Alexandra Segers

General Manager, Tochi Advisors
Amy Gerber

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Bradley Migdal

Executive Managing Director, Business Incentives Practice, Cushman & Wakefield
Brian Corde

Managing Partner, Atlas Insight
Brian Gallagher

Vice President, Corporate Strategy and Development, PPC Partners, Inc.
Chris Chmura, Ph.D.

CEO & Founder, Chmura Economics
Chris Schwinden

Partner, Site Selection Group
Chris Volney

Managing Director, Americas Consulting, CBRE
Courtland Robinson

Director of Business Development, Brasfield & Gorrie
Courtney Dunbar

Site Selection & Economic Development Leader, Burns & McDonnell
David Hickey

Managing Director, Hickey & Associates
Dennis Cuneo

Former Senior Vice President, Toyota Motor North America; Owner , DC Strategic Advisors
Dianne Jones

Managing Director, Business and Economic Incentives, JLL
Eric Stavriotis

Vice Chairman, CBRE
Joe Dunlap

Chief Supply Chain Officer, Legacy Investing
Lauren Berry

Senior Manager, Location Analysis and Incentives, Maxis Advisors
Marc Beauchamp

President, SCI Global
Matthew Powers

Site Selection Lead, REDI Site Selection
Scott J. Ziance

Partner and Economic Incentives Practice Leader, Vorys, Sater, Seymour and Pease LLP
Scott Kupperman

Founder, Kupperman Location Solutions
Stephen Gray

President & CEO, Gray Construction

India-Based Garonit Pharmaceutical Plans New Windsor, New York, Manufacturing Operations

Area Development News Desk

08/11/2025

India-based Garonit Pharmaceutical, Inc., a manufacturer of antiseptic products and health care solutions, plans to establish operations in New Windsor, New York. The $46.1 million project is expected to create 100 jobs in Orange County.

The investment will include the construction of a 200,000-square-foot pharmaceutical manufacturing facility, located near Stewart International Airport, which will produce antiseptic products essential for surgical disinfection and infection prevention in hospitals. Production is scheduled to begin in January 2027.

The project is being supported by $3.5 million through the Excelsior Jobs Program and a $300,000 Mid-Hudson Regional Economic Development Council capital grant.

“As the U.S.-based owner of an API manufacturing company, I have long aspired to produce finished pharmaceutical products here in the United States,”said Garonit Pharmaceutical Inc. Owner Rohit Garg. “This achievement has been made possible through the invaluable support and collaboration of dedicated teams of The State of New York, Orange County, and City leaders of New Windsor.”

In addition to our commercial endeavors, Garonit Pharmaceuticals collaborates with renowned philanthropic organizations such as UNICEF, WHO, and The Red Cross, aiming to create a better world. Through our own trust, the Neelam Garg Foundation, we actively support girls' education initiatives for underprivileged communities.

Garonit Pharmaceutical is a premier API manufacturer and active pharmaceutical ingredient supplier. The company currently operates manufacturing facilities in the U.S. and India.

“Garonit Pharmaceutical’s expansion into New York reflects the confidence that global companies have in our state’s workforce, infrastructure, and innovation ecosystem,” noted Empire State Development President, CEO, and Commissioner Hope Knight. “The Mid-Hudson region's strategic location, robust infrastructure, and proximity to world-class transportation networks make it an ideal location for advanced manufacturing operations. This project will generate long-term economic benefits and position the region for continued growth in the pharmaceutical sector.”

Project Announcements